Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Treatment outcomes by stratifying the N-acetyl transferase 2 phenotype in pre-treated patients with advanced refractory biliary tract cancer treated with nanvuranlat, an L-type amino acid transporter inhibitor: An ad-hoc analysis of a randomized, double-blind, placebo-controlled phase 2 study.
Authors
Naohiro Okano
Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, Japan
Naohiro Okano , Fumio Nagashima , Mariko Nishioka , Haruki Kusaka , Kouji Yamamoto , Junji Furuse
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
UMIN000034080
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 483)
DOI
10.1200/JCO.2024.42.3_suppl.483
Abstract #
483
Poster Bd #
C8
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A phase II study of nivolumab in patients with advanced refractory biliary tract cancers (BTC).
First Author: Richard D. Kim
Poster
2017 Gastrointestinal Cancers Symposium
Gemcitabine and cisplatin plus ramucirumab or merestinib or placebo in first-line treatment for advanced or metastatic biliary tract cancer: A double-blind, randomized phase II trial.
First Author: Ashwin Reddy Sama
Poster
2024 ASCO Annual Meeting
QUIC: Phase 2 study of gemcitabine, cisplatin, quemliclustat (AB680), and zimberelimab (AB122) during first-line treatment of advanced biliary tract cancers (BTC)—Big Ten Cancer Research Consortium study BTCRC-GI22-564.
First Author: John Ebben
Poster
2024 ASCO Gastrointestinal Cancers Symposium
ZSAB-TOP: A phase 2 trial of tislelizumab (TIS) and ociperlimab (OCI) combined with gemcitabine and cisplatin (GemCis) as the first-line treatment for advanced biliary tract cancer (BTC).
First Author: Jia Fan